LSV Asset Management Takes $206,000 Position in Emergent BioSolutions Inc. (NYSE:EBS)

LSV Asset Management bought a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,600 shares of the biopharmaceutical company’s stock, valued at approximately $206,000.

A number of other institutional investors have also recently bought and sold shares of EBS. American Century Companies Inc. raised its holdings in shares of Emergent BioSolutions by 23.4% in the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after purchasing an additional 404,667 shares during the period. State Street Corp raised its holdings in Emergent BioSolutions by 864.7% in the third quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after buying an additional 1,713,200 shares during the period. Invesco Ltd. lifted its position in Emergent BioSolutions by 70.9% during the fourth quarter. Invesco Ltd. now owns 1,539,907 shares of the biopharmaceutical company’s stock valued at $14,722,000 after buying an additional 638,995 shares in the last quarter. Oak Hill Advisors LP purchased a new stake in Emergent BioSolutions during the third quarter worth approximately $9,296,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Emergent BioSolutions by 8.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 902,332 shares of the biopharmaceutical company’s stock worth $8,626,000 after acquiring an additional 69,157 shares in the last quarter. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on EBS shares. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Emergent BioSolutions in a report on Tuesday, April 1st. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th.

Insider Transactions at Emergent BioSolutions

In other news, Director Neal Franklin Fowler sold 35,000 shares of Emergent BioSolutions stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total value of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at approximately $589,413. This trade represents a 25.72 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.20% of the company’s stock.

Emergent BioSolutions Trading Up 0.9 %

Shares of EBS opened at $4.62 on Wednesday. Emergent BioSolutions Inc. has a one year low of $1.82 and a one year high of $15.10. The stock has a 50-day moving average price of $6.29 and a 200 day moving average price of $8.40. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The company has a market capitalization of $251.20 million, a P/E ratio of -1.13 and a beta of 2.14.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.40. The business had revenue of $194.70 million during the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative net margin of 18.55% and a negative return on equity of 9.91%. During the same quarter last year, the company earned ($0.77) earnings per share. Sell-side analysts forecast that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions announced that its board has authorized a stock repurchase plan on Monday, March 31st that allows the company to buyback $50.00 million in shares. This buyback authorization allows the biopharmaceutical company to reacquire up to 19% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.